Upanovimab

DB16505InvestigationalProtein Based Therapies

Upanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19.

Mechanism: SCTA01 is a monoclonal antibody that targets the SARS-CoV-2 S protein and aims to neutralize SARS-CoV-2. Currently, it is being investigated against COVID-19.
Curator reviewed
Also known as: IMMUNOGLOBULIN G1, ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN) (HUMAN-MUS MUSCULUS MONOCLONAL SCTA01 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL SCTA01 .KAPPA.-CHAIN, DIMER
Code names: SCTA-01

Resolves to

Compound

UNII8E88WSA6X3CAS2500633-46-3

Targets

P0DTC2S

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Upanovimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account